Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease

Launched by SUZHOU HENGRUIHONGYUAN MEDICAL TECHNOLOGY CO. LTD · Jul 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called the Pulsed Electric Field Ablation System to help adults with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe chronic bronchitis, a condition that causes a long-lasting cough with mucus. The goal is to see if this treatment is safe and can improve symptoms like cough and breathing difficulties. About 210 patients will take part, with some receiving the actual treatment and others receiving a placebo procedure to compare results.

To join the study, participants need to be between 35 and 80 years old and have a history of chronic bronchitis with ongoing symptoms despite standard inhaler treatments. They will need to be able to undergo two procedures using a bronchoscope (a thin tube inserted into the lungs) under anesthesia and attend follow-up visits. People with certain health issues, like lung infections, recent smoking, heart problems, or lung cancer, won’t be eligible. Participants can expect to have two bronchoscopy procedures and regular check-ups during the study to monitor their health and how well the treatment works. This study is not yet recruiting, but it offers hope for better symptom relief for those living with COPD and chronic bronchitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject's age is ≥35 years and ≤80 years.
• • 2. Patient has chronic bronchitis, defined as productive cough for three months in each of two successive years, whereas other causes of productive cough have been ruled out.
• • 3. Patient has a CAT score ≥ 10.
• • 4. Patient has an SGRQ score ≥ 25.
• • 5. Patient's responses to the first two questions of the CAT instrument sum to ≥ 7 points or the sum is 6 points and the patient's total CAT score is \> 20 points.
• • 6. Patient has FEV1/FVC \< 0.70.
• • 7. Patient has a pre-procedure post-bronchodilator FEV1 percent predicted of ≥ 30%.
• • 8. Patient is receiving guideline directed pharmacotherapy which includes one or more long acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for at least 8 weeks prior to randomization, unless the patient has attempted such therapy within the past 1 year without significant clinical response or had an adverse reaction.
• • 9. In the opinion of the Primary investigator, patient is able to undergo 2 bronchoscopies under general anesthesia and is able to adhere to the study follow-up schedule.
• • 10. Informed consent signed by the patient or legal representative.
• Exclusion Criteria:
• • 1. Patient has known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).
• • 2. Patient has a steroid-dependent condition requiring \>10 mg of oral corticosteroid per day.
• • 3. Patient has any implantable electronic device (e.g., pacemaker, cardioverter defibrillator) that cannot be turned off during the procedure.
• • 4. Patient has a history of ventricular tachy-arrhythmia or clinically significant atrial tachyarrhythmia within the past two years, or sinus bradycardia with a heart rate of under than 45 beats per minute, unless the arrhythmia has been treated and/or patient is in regular rhythm during the screening phase.
• • 5. Subject has lung cancer.
• • 6. Patient has a pulmonary nodule or cavity that in the judgement of the Primary investigator may require intervention during the course of the study.
• • 7. Patient had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung implant/prosthesis, metal airway stent, valves, coils or bullectomy.
• • 8. Patient has emphysema of greater than or equal to 50% as quantified on baseline HRCT scan as determined by the CT Core Lab.
• • 9. Patient has asthma based on Global Initiative for Asthma (GINA) criteria.
• • 10. Patient has clinically significant bronchiectasis influencing the patient's clinical symptoms of cough and phlegm.
• • 11. Patient has actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 2 months.
• • 12. Patient is unable to walk over 225 meters in 6 minutes.
• • 13. Patient has a serious medical condition that, in the Primary investigator's opinion, could compromise patient safety or confound the interpretation of the patient's response to therapy (e.g., congestive heart failure, cardiomyopathy, or myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes (HbA1c \>8%), uncontrolled hypertension (diastolic BP \>100mmHg) or autoimmune disease requiring treatment with immunosuppressant medications or a disease requiring chemotherapy).
• • 14. Patient has uncontrolled GERD.
• • 15. Patient has known severe pulmonary hypertension (pulmonary artery SP ≥ 50 mmHg).
• • 16. Patient has a known sensitivity to medication required to perform bronchoscopy (i.e., lidocaine, atropine, benzodiazepines).
• • 17. Patient is pregnant, nursing, or planning to get pregnant during study duration.
• • 18. Patient is currently participating in another clinical study involving an investigational product.
• • 19. Patient is receiving anticoagulation for a cardiovascular indication and, in the Primary investigator's opinion, unable to suspend anticoagulant medications (i.e., aspirin, clopidogrel, warfarin) during bronchoscopy in accordance.
• • 20. Patient has known airway colonization with drug-resistant bacteria such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, Burkholderia cepacia complex, Mycobacterium tuberculosis, Mycobacterium abscessus, Trichoderma, or other significant fungi.